US6110486A - Buccal polar spray or capsule - Google Patents

Buccal polar spray or capsule Download PDF

Info

Publication number: US6110486A
Authority: US; United States
Prior art keywords: polar solvent; active compound; spray; capsule; flavoring agent
Prior art date: 1996-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

US09/199,380

Other languages

English (en)

Inventor

Harry A. Dugger, III

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SUDA Ltd

Original Assignee

Flemington Pharmaceutical Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-04-12

Filing date

1998-11-25

Publication date

2000-08-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24525609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US6110486(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-11-25 Application filed by Flemington Pharmaceutical Corp filed Critical Flemington Pharmaceutical Corp

1998-11-25 Priority to US09/199,380 priority Critical patent/US6110486A/en

2000-05-08 Assigned to FLEMINGTON PHARMACEUTICALCORP. reassignment FLEMINGTON PHARMACEUTICALCORP. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DUGGER, HARRY A., III

2000-08-29 Application granted granted Critical

2000-08-29 Publication of US6110486A publication Critical patent/US6110486A/en

2002-11-12 Assigned to NOVADEL PHARMA INC. reassignment NOVADEL PHARMA INC. CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: DUGGER, HARRY A., III

2008-06-03 Assigned to PROQUEST INVESTMENTS III, L.P. AS COLLATERAL AGENT FOR SECURED PARTIES reassignment PROQUEST INVESTMENTS III, L.P. AS COLLATERAL AGENT FOR SECURED PARTIES SECURITY AGREEMENT Assignors: NOVADEL PHARMA INC.

2010-08-31 Assigned to NOVADEL PHARMA INC. reassignment NOVADEL PHARMA INC. RELEASE BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: PROQUEST INVESTMENTS III, L.P. AS COLLATERAL AGENT

2013-10-14 Assigned to SUDA LTD. reassignment SUDA LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: NOVADEL PHARMA INC.

2016-04-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000007921 spray Substances 0.000 title claims abstract description 39
239000002775 capsule Substances 0.000 title abstract description 38
239000000203 mixture Substances 0.000 claims abstract description 56
239000002798 polar solvent Substances 0.000 claims abstract description 43
150000001875 compounds Chemical class 0.000 claims abstract description 40
239000000796 flavoring agent Substances 0.000 claims abstract description 22
235000013355 food flavoring agent Nutrition 0.000 claims abstract description 22
210000002200 mouth mucosa Anatomy 0.000 claims abstract description 9
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 20
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 18
238000000034 method Methods 0.000 claims description 12
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims description 11
229960002881 clemastine Drugs 0.000 claims description 11
150000003839 salts Chemical class 0.000 claims description 11
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 10
229960005309 estradiol Drugs 0.000 claims description 10
229930182833 estradiol Natural products 0.000 claims description 10
239000003921 oil Substances 0.000 claims description 10
235000019198 oils Nutrition 0.000 claims description 10
229960003604 testosterone Drugs 0.000 claims description 10
229960003387 progesterone Drugs 0.000 claims description 9
239000000186 progesterone Substances 0.000 claims description 9
239000002904 solvent Substances 0.000 claims description 9
244000246386 Mentha pulegium Species 0.000 claims description 8
235000016257 Mentha pulegium Nutrition 0.000 claims description 8
235000004357 Mentha x piperita Nutrition 0.000 claims description 8
235000001050 hortel pimenta Nutrition 0.000 claims description 8
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims description 7
229960002702 piroxicam Drugs 0.000 claims description 6
RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 5
229960002464 fluoxetine Drugs 0.000 claims description 5
150000001298 alcohols Chemical class 0.000 claims description 4
241000124008 Mammalia Species 0.000 claims description 3
230000001430 anti-depressive effect Effects 0.000 claims description 3
239000000935 antidepressant agent Substances 0.000 claims description 3
229940005513 antidepressants Drugs 0.000 claims description 3
239000000739 antihistaminic agent Substances 0.000 claims description 3
235000019499 Citrus oil Nutrition 0.000 claims description 2
235000014749 Mentha crispa Nutrition 0.000 claims description 2
244000078639 Mentha spicata Species 0.000 claims description 2
230000001387 anti-histamine Effects 0.000 claims description 2
229940125715 antihistaminic agent Drugs 0.000 claims description 2
239000010500 citrus oil Substances 0.000 claims description 2
235000003599 food sweetener Nutrition 0.000 claims description 2
239000008369 fruit flavor Substances 0.000 claims description 2
229930195733 hydrocarbon Natural products 0.000 claims description 2
150000002430 hydrocarbons Chemical class 0.000 claims description 2
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
239000003270 steroid hormone Substances 0.000 claims description 2
239000003765 sweetening agent Substances 0.000 claims description 2
SEQDDYPDSLOBDC-UHFFFAOYSA-N Temazepam Chemical compound N=1C(O)C(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 SEQDDYPDSLOBDC-UHFFFAOYSA-N 0.000 claims 1
-1 benzo-diazepams Substances 0.000 claims 1
238000005507 spraying Methods 0.000 claims 1
229960003188 temazepam Drugs 0.000 claims 1
239000003995 emulsifying agent Substances 0.000 abstract description 12
238000010521 absorption reaction Methods 0.000 abstract description 11
239000007903 gelatin capsule Substances 0.000 abstract description 8
239000000443 aerosol Substances 0.000 abstract description 3
230000000694 effects Effects 0.000 abstract description 2
ZWHOTPNCEFWATE-AWEZNQCLSA-N (3S)-3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-phenylpyrrolidine-1-carboxamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)O[C@@H]1CN(CC1)C(=O)NC1=CC=CC=C1 ZWHOTPNCEFWATE-AWEZNQCLSA-N 0.000 abstract 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 28
238000009472 formulation Methods 0.000 description 24
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
229920001223 polyethylene glycol Polymers 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
235000011187 glycerol Nutrition 0.000 description 14
239000002202 Polyethylene glycol Substances 0.000 description 13
229920000159 gelatin Polymers 0.000 description 8
235000019322 gelatine Nutrition 0.000 description 8
108010010803 Gelatin Proteins 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 7
239000008273 gelatin Substances 0.000 description 7
235000011852 gelatine desserts Nutrition 0.000 description 7
PMGQWSIVQFOFOQ-BDUVBVHRSA-N (e)-but-2-enedioic acid;(2r)-2-[2-[1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCOC(C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-BDUVBVHRSA-N 0.000 description 6
229960002689 clemastine fumarate Drugs 0.000 description 6
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 5
GIYXAJPCNFJEHY-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]-1-propanamine hydrochloride (1:1) Chemical compound Cl.C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 GIYXAJPCNFJEHY-UHFFFAOYSA-N 0.000 description 5
230000004913 activation Effects 0.000 description 5
229940079593 drug Drugs 0.000 description 5
239000003814 drug Substances 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
235000010445 lecithin Nutrition 0.000 description 5
229940067606 lecithin Drugs 0.000 description 5
239000000787 lecithin Substances 0.000 description 5
239000001525 mentha piperita l. herb oil Substances 0.000 description 5
235000019477 peppermint oil Nutrition 0.000 description 5
239000002585 base Substances 0.000 description 4
238000010579 first pass effect Methods 0.000 description 4
231100000252 nontoxic Toxicity 0.000 description 4
230000003000 nontoxic effect Effects 0.000 description 4
229940068917 polyethylene glycols Drugs 0.000 description 4
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
150000001412 amines Chemical class 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000012528 membrane Substances 0.000 description 3
239000003380 propellant Substances 0.000 description 3
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
238000009736 wetting Methods 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 2
239000000006 Nitroglycerin Substances 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 2
239000013543 active substance Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
239000008280 blood Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
230000036765 blood level Effects 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
PMGQWSIVQFOFOQ-YKVZVUFRSA-N clemastine fumarate Chemical compound OC(=O)\C=C\C(O)=O.CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 PMGQWSIVQFOFOQ-YKVZVUFRSA-N 0.000 description 2
KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 2
229960003711 glyceryl trinitrate Drugs 0.000 description 2
KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
239000011777 magnesium Substances 0.000 description 2
229910052749 magnesium Inorganic materials 0.000 description 2
HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
229960001597 nifedipine Drugs 0.000 description 2
DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 2
229960000395 phenylpropanolamine Drugs 0.000 description 2
229920005862 polyol Polymers 0.000 description 2
150000003077 polyols Chemical class 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 2
229960003908 pseudoephedrine Drugs 0.000 description 2
BALXUFOVQVENIU-KXNXZCPBSA-N pseudoephedrine hydrochloride Chemical compound [H+].[Cl-].CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 BALXUFOVQVENIU-KXNXZCPBSA-N 0.000 description 2
210000002784 stomach Anatomy 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
FEOHYDSNGHIXOM-WLDMJGECSA-N (3R,4R,5S,6R)-3-amino-6-(hydroxymethyl)-2-methyloxane-2,4,5-triol Chemical compound CC1(O)[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO FEOHYDSNGHIXOM-WLDMJGECSA-N 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
229940013085 2-diethylaminoethanol Drugs 0.000 description 1
HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
108010011485 Aspartame Proteins 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
241000252254 Catostomidae Species 0.000 description 1
241000207199 Citrus Species 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
206010058359 Hypogonadism Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
DYWNLSQWJMTVGJ-KUSKTZOESA-N Phenylpropanolamine hydrochloride Chemical compound Cl.C[C@H](N)[C@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-KUSKTZOESA-N 0.000 description 1
239000004721 Polyphenylene oxide Substances 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
239000004902 Softening Agent Substances 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
HPFVBGJFAYZEBE-XNBTXCQYSA-N [(8r,9s,10r,13s,14s)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] 3-cyclopentylpropanoate Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CCC(=O)C=C3CC2)C)CC[C@@]11C)CC1OC(=O)CCC1CCCC1 HPFVBGJFAYZEBE-XNBTXCQYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000011149 active material Substances 0.000 description 1
208000024716 acute asthma Diseases 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
239000000605 aspartame Substances 0.000 description 1
IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
235000010357 aspartame Nutrition 0.000 description 1
229960003438 aspartame Drugs 0.000 description 1
JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
150000001557 benzodiazepines Chemical class 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
210000005178 buccal mucosa Anatomy 0.000 description 1
239000006189 buccal tablet Substances 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000007963 capsule composition Substances 0.000 description 1
235000019219 chocolate Nutrition 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
210000004246 corpus luteum Anatomy 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
238000011161 development Methods 0.000 description 1
238000010586 diagram Methods 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000009164 estrogen replacement therapy Methods 0.000 description 1
229940065410 feldene Drugs 0.000 description 1
229960000389 fluoxetine hydrochloride Drugs 0.000 description 1
239000012458 free base Substances 0.000 description 1
229960002442 glucosamine Drugs 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
MNWFXJYAOYHMED-UHFFFAOYSA-M heptanoate Chemical compound CCCCCCC([O-])=O MNWFXJYAOYHMED-UHFFFAOYSA-M 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
238000013508 migration Methods 0.000 description 1
230000005012 migration Effects 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
229960002715 nicotine Drugs 0.000 description 1
SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
229960002305 phenylpropanolamine hydrochloride Drugs 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000570 polyether Polymers 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
238000012545 processing Methods 0.000 description 1
229940035613 prozac Drugs 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
229940010017 tavist Drugs 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000012546 transfer Methods 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Images

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals

Definitions

a bite capsule of the invention comprises the following fill formulation:
composition fill for a clemastine 1.34 mg/25 mg phenylpropanolamine capsule:

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Chemical & Material Sciences (AREA)
Physiology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Nutrition Science (AREA)
Zoology (AREA)
Medicinal Preparation (AREA)
Cosmetics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

US09/199,380 1996-04-12 1998-11-25 Buccal polar spray or capsule Expired - Lifetime US6110486A (en)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
US09/199,380 US6110486A (en)	1996-04-12	1998-11-25	Buccal polar spray or capsule

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US63006596A	1996-04-12	1996-04-12
US09/199,380 US6110486A (en)	1996-04-12	1998-11-25	Buccal polar spray or capsule

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
US63006596A Continuation-In-Part	1996-04-12	1996-04-12

Publications (1)

Publication Number	Publication Date
US6110486A true US6110486A (en)	2000-08-29

Family

ID=24525609

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
US09/199,380 Expired - Lifetime US6110486A (en)	1996-04-12	1998-11-25	Buccal polar spray or capsule

Country Status (8)

Country	Link
US (1)	US6110486A (de)
EP (1)	EP0910339B1 (de)
AT (1)	ATE288255T1 (de)
AU (1)	AU2190697A (de)
DE (1)	DE69732412T2 (de)
ES (1)	ES2234010T3 (de)
PT (1)	PT910339E (de)
WO (1)	WO1997038662A2 (de)

Cited By (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20030035831A1 (en) *	1998-12-21	2003-02-20	Pankaj Modi	Pharmaceutical compositions for buccal delivery of pain relief medications
US20030077228A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20030077227A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030077229A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030082107A1 (en) *	1997-10-01	2003-05-01	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030095925A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030095927A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US6585997B2 (en)	2001-08-16	2003-07-01	Access Pharmaceuticals, Inc.	Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US20030157029A1 (en) *	1998-12-21	2003-08-21	Pankaj Modi	Methods of administering and enhancing absorption of pharmaceutical agents
US20030159702A1 (en) *	2002-01-21	2003-08-28	Lindell Katarina E.A.	Formulation and use manufacture thereof
US20030190286A1 (en) *	1997-10-01	2003-10-09	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US6676931B2 (en)	1997-10-01	2004-01-13	Novadel Pharma Inc.	Buccal, polar and non-polar spray or capsule
US20040120896A1 (en) *	1997-10-01	2004-06-24	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040136914A1 (en) *	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing ondansetron
US20040136915A1 (en) *	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing atropine
US20040136913A1 (en) *	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing sumatriptan
US20040141923A1 (en) *	1997-10-01	2004-07-22	Dugger Harry A.	Buccal, polar and non-polar spray containing alprazolam
US20040198646A1 (en) *	2003-02-20	2004-10-07	Moshe Flashner-Barak	Menthol solutions of drugs
US20040265239A1 (en) *	1997-10-01	2004-12-30	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing zolpidem
US20050002867A1 (en) *	1997-10-01	2005-01-06	Novadel Pharma Inc.	Buccal, polar and non-polar sprays containing propofol
US6846495B2 (en)	1999-01-11	2005-01-25	The Procter & Gamble Company	Compositions having improved delivery of actives
US20050025716A1 (en) *	1997-10-01	2005-02-03	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20050136104A1 (en) *	2003-12-17	2005-06-23	Dennis Rowe	Chewable soft capsules containing ungelatinized starch
US20050163719A1 (en) *	1997-10-01	2005-07-28	Dugger Harry A.Iii	Buccal, polar and non-polar spray containing diazepam
US20050169983A1 (en) *	2002-04-25	2005-08-04	Hassan Emadeldin M.	Chewable soft capsule
US20050180923A1 (en) *	1997-10-01	2005-08-18	Dugger Harry A.Iii	Buccal, polar and non-polar spray containing testosterone
US20050226925A1 (en) *	2004-02-17	2005-10-13	Transoral Pharmaceuticals, Inc.	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20050271719A1 (en) *	2004-06-03	2005-12-08	Wong Desmond Y T	Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US20050281752A1 (en) *	1997-10-01	2005-12-22	Dugger Harry A Iii	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050287075A1 (en) *	1997-10-01	2005-12-29	Dugger Harry A Iii	Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20060062812A1 (en) *	2003-03-11	2006-03-23	Calvin Ross	Novel compositions
US20060073174A1 (en) *	2001-08-16	2006-04-06	Access Pharmaceuticals, Inc.	Adherent and erodible film to treat a moist surface of a body tissue
US7138133B2 (en)	2001-10-10	2006-11-21	The Procter & Gamble Company	Orally administered liquid compositions
US20060276501A1 (en) *	2005-05-25	2006-12-07	Transoral Pharmaceuticals, Inc.	Solid compositions for treating middle-of-the-night insomnia
US20070225322A1 (en) *	2005-05-25	2007-09-27	Transoral Pharmaceuticals, Inc.	Compositions and methods for treating middle-of-the night insomnia
US20070248548A1 (en) *	2006-04-19	2007-10-25	Blondino Frank E	Stable hydroalcoholic oral spray formulations and methods
US20070287740A1 (en) *	2005-05-25	2007-12-13	Transcept Pharmaceuticals, Inc.	Compositions and methods of treating middle-of-the night insomnia
WO2007146805A2 (en)	2006-06-08	2007-12-21	Warner Chilcott Company, Inc.	Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20080171089A1 (en) *	2006-12-22	2008-07-17	Blondino Frank E	Stable anti-nausea oral spray formulations and methods
WO2008091588A1 (en)	2007-01-22	2008-07-31	Targacept, Inc.	Intranasal, buccal, and sublingual administration of metanicotine analogs
US20080213363A1 (en) *	2003-01-23	2008-09-04	Singh Nikhilesh N	Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20080275030A1 (en) *	2007-01-19	2008-11-06	Sveinbjorn Gizurarson	Methods and Compositions for the Delivery of a Therapeutic Agent
US20080280947A1 (en) *	2007-05-10	2008-11-13	Blondino Frank E	Anti-insomnia compositions and methods
US20090162300A1 (en) *	1997-10-01	2009-06-25	Dugger Iii Harry A	Buccal, polar and non-polar spray containing alprazolam
US20100105641A1 (en) *	2006-12-12	2010-04-29	Kees Van Der Voort Maarschalk	Oral Contraceptive Spray
WO2011064316A2 (en)	2009-11-25	2011-06-03	Paolo Botti	Mucosal delivery of peptides
WO2012022446A1 (en)	2010-08-16	2012-02-23	Innotesto Bvba	Testosterone solutions for the treatment of testosterone deficiency
WO2013102665A1 (en)	2012-01-04	2013-07-11	Innotesto Bvba	Oromucosal liquid estradiol compositions
EP2767163A1 (de)	2005-02-17	2014-08-20	Abbott Laboratories	Transmukosale Verabreichung von Arzneimittelzusammensetzungen zur Behandlung und Vorbeugung von Erkrankungen bei Tieren
US20180177800A1 (en) *	2015-09-30	2018-06-28	Fujifilm Corporation	Composition for percutaneous absorption
WO2025090448A1 (en) *	2023-10-23	2025-05-01	R.P. Scherer Technologies, Llc	Capsules for oral and nasal delivery of pharmaceutical products

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9523833D0 (en) *	1995-11-22	1996-01-24	Boots Co Plc	Medical treatment
AU8107998A (en) *	1997-05-22	1998-12-11	Boots Company Plc, The	Pharmaceutical compositions
GB9911037D0 (en) *	1999-05-13	1999-07-14	Micap Limited	Nicotine delivery service
EP1444976A1 (de) *	2003-02-10	2004-08-11	Novadel Pharma Inc.	Bukkale, polare und nichtpolare Spray und Kapsel
US7850987B2 (en) *	2004-04-08	2010-12-14	Micronutrient, Llc	Nutrient composition(s) and system(s) for individualized, responsive dosing regimens
JP2007533697A (ja)	2004-04-22	2007-11-22	デュオコートエービー	グルココルチコイド救急治療用の医薬組成物
US20110293535A1 (en) *	2009-02-11	2011-12-01	Heglund, A.S.	Composition for buccal absorption of nicotine for the purpose of smoking cessation
WO2019018338A1 (en)	2017-07-17	2019-01-24	Northriver Pharm, LLC	NASAL COMPOSITION COMPRISING A MUCOADHESIVE POLYMER

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4232002A (en) *	1977-12-01	1980-11-04	The Welsh National School Of Medicine	Procedures and pharmaceutical products for use in the administration of antihistamines
DE3922650A1 (de) *	1988-07-08	1990-01-11	Egyt Gyogyszervegyeszeti Gyar	Nitroglycerinhaltige, treibgasfreie aerosolpraeparate und verfahren zu deren herstellung

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SU432703A3 (de) *	1971-08-24	1974-06-15	Фридрих Боссерт, Вульф Фатер, Курт Бауер
DE3338978A1 (de) *	1982-10-29	1984-05-03	Basf Ag, 6700 Ludwigshafen	Verapamil und gallopamil und ihre physiologisch vertraeglichen salze zur resorptiven anwendung auf den schleimhaeuten des mundes, des nasen-rachen-raums und des rektums
DE3544692A1 (de) *	1985-12-18	1987-06-19	Bayer Ag	Dihydropyridinspray, verfahren zu seiner herstellung und seine pharmazeutische verwendung
DE3738236A1 (de) *	1987-11-11	1989-05-24	Euro Celtique Sa	Beisskapsel
US4935243A (en) *	1988-12-19	1990-06-19	Pharmacaps, Inc.	Chewable, edible soft gelatin capsule
US5135753A (en) *	1991-03-12	1992-08-04	Pharmetrix Corporation	Method and therapeutic system for smoking cessation
JP3661131B2 (ja) *	1992-02-20	2005-06-15	アスペンファーマケアヨーロッパリミテッド	喫煙抑制具
JPH07506839A (ja) *	1992-12-04	1995-07-27	メイヤー・ファーマシューティカル・ラボラトリース・インコーポレーテッド	スプレー可能な鎮痛剤組成物およびその使用方法
US5362496A (en) *	1993-08-04	1994-11-08	Pharmetrix Corporation	Method and therapeutic system for smoking cessation
US5456677A (en) *	1994-08-22	1995-10-10	Spector; John E.	Method for oral spray administration of caffeine
NZ280610A (en) *	1994-12-29	1997-08-22	Mcneil Ppc Inc	Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent

1997
- 1997-02-21 ES ES97914779T patent/ES2234010T3/es not_active Expired - Lifetime
- 1997-02-21 AT AT97914779T patent/ATE288255T1/de not_active IP Right Cessation
- 1997-02-21 PT PT97914779T patent/PT910339E/pt unknown
- 1997-02-21 DE DE69732412T patent/DE69732412T2/de not_active Revoked
- 1997-02-21 WO PCT/US1997/002793 patent/WO1997038662A2/en not_active Ceased
- 1997-02-21 EP EP97914779A patent/EP0910339B1/de not_active Revoked
- 1997-02-21 AU AU21906/97A patent/AU2190697A/en not_active Abandoned
1998
- 1998-11-25 US US09/199,380 patent/US6110486A/en not_active Expired - Lifetime

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4232002A (en) *	1977-12-01	1980-11-04	The Welsh National School Of Medicine	Procedures and pharmaceutical products for use in the administration of antihistamines
DE3922650A1 (de) *	1988-07-08	1990-01-11	Egyt Gyogyszervegyeszeti Gyar	Nitroglycerinhaltige, treibgasfreie aerosolpraeparate und verfahren zu deren herstellung

Cited By (123)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20050281752A1 (en) *	1997-10-01	2005-12-22	Dugger Harry A Iii	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050025717A1 (en) *	1997-10-01	2005-02-03	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20030077227A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20030077229A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030082107A1 (en) *	1997-10-01	2003-05-01	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030095925A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20030095927A1 (en) *	1997-10-01	2003-05-22	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20090186035A1 (en) *	1997-10-01	2009-07-23	Dugger Iii Harry A	Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20090186099A1 (en) *	1997-10-01	2009-07-23	Dugger Iii Harry A	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20090162298A1 (en) *	1997-10-01	2009-06-25	Dugger Iii Harry A	Buccal, polar and non-polar spray containing sumatriptan
US20030190286A1 (en) *	1997-10-01	2003-10-09	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US6676931B2 (en)	1997-10-01	2004-01-13	Novadel Pharma Inc.	Buccal, polar and non-polar spray or capsule
US20040062716A1 (en) *	1997-10-01	2004-04-01	Novadel Pharma Inc.	Buccal, polar and non-polar spray of capsule
US20040120896A1 (en) *	1997-10-01	2004-06-24	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20040120895A1 (en) *	1997-10-01	2004-06-24	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136914A1 (en) *	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing ondansetron
US6977070B2 (en)	1997-10-01	2005-12-20	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136913A1 (en) *	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing sumatriptan
US20040141923A1 (en) *	1997-10-01	2004-07-22	Dugger Harry A.	Buccal, polar and non-polar spray containing alprazolam
US20090162297A1 (en) *	1997-10-01	2009-06-25	Dugger Iii Harry A	Buccal, polar and non-polar spray containing ondansetron
US20040265239A1 (en) *	1997-10-01	2004-12-30	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing zolpidem
US20050002867A1 (en) *	1997-10-01	2005-01-06	Novadel Pharma Inc.	Buccal, polar and non-polar sprays containing propofol
US20090162300A1 (en) *	1997-10-01	2009-06-25	Dugger Iii Harry A	Buccal, polar and non-polar spray containing alprazolam
US20090123387A1 (en) *	1997-10-01	2009-05-14	Dugger Iii Harry A	Buccal, polar and non-polar spray or capsule containing cardiovascular or reneal drugs
US7632517B2 (en)	1997-10-01	2009-12-15	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing zolpidem
US20050025714A1 (en) *	1997-10-01	2005-02-03	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050025713A1 (en) *	1997-10-01	2005-02-03	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20050025715A1 (en) *	1997-10-01	2005-02-03	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20050025716A1 (en) *	1997-10-01	2005-02-03	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20090118170A1 (en) *	1997-10-01	2009-05-07	Dugger Iii Harry A	Buccal, polar and non-polar spray or capsule
US20050142069A1 (en) *	1997-10-01	2005-06-30	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20100092403A1 (en) *	1997-10-01	2010-04-15	Dugger Iii Harry A	Buccal, polar and non-polar spray containing zolpidem
US20050163719A1 (en) *	1997-10-01	2005-07-28	Dugger Harry A.Iii	Buccal, polar and non-polar spray containing diazepam
US20100209541A1 (en) *	1997-10-01	2010-08-19	Velcera, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20050180923A1 (en) *	1997-10-01	2005-08-18	Dugger Harry A.Iii	Buccal, polar and non-polar spray containing testosterone
US8236285B2 (en)	1997-10-01	2012-08-07	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing zolpidem
US6969508B2 (en)	1997-10-01	2005-11-29	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20120295945A1 (en) *	1997-10-01	2012-11-22	Dugger Iii Harry A	Buccal, polar and non-polar spray containing ondansetron
US20040136915A1 (en) *	1997-10-01	2004-07-15	Dugger Harry A.	Buccal, polar and non-polar spray containing atropine
US9078816B2 (en) *	1997-10-01	2015-07-14	Suda Ltd.	Buccal, polar and non-polar spray containing ondansetron
US20030077228A1 (en) *	1997-10-01	2003-04-24	Dugger Harry A.	Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20050281753A1 (en) *	1997-10-01	2005-12-22	Dugger Harry A Iii	Buccal, polar and non-polar spray or capsule
US20050287075A1 (en) *	1997-10-01	2005-12-29	Dugger Harry A Iii	Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US6998110B2 (en)	1997-10-01	2006-02-14	Novadel Pharma, Inc.	Buccal, polar and non-polar spray or capsule
US20070048229A1 (en) *	1997-10-01	2007-03-01	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing atropine
US20060222597A1 (en) *	1997-10-01	2006-10-05	Novadel Pharma Inc.	Buccal, polar and non-polar sprays containing propofol
US20060159624A1 (en) *	1997-10-01	2006-07-20	Dugger Harry A Iii	Buccal, polar and non-polar spray containing zolpidem
US20060165604A1 (en) *	1997-10-01	2006-07-27	Dugger Harry A Iii	Buccal, polar and non-polar spray containing sumatriptan
US20060171896A1 (en) *	1997-10-01	2006-08-03	Dugger Harry A Iii	Buccal, polar and non-polar spray containing alprazolam
US20060216240A1 (en) *	1997-10-01	2006-09-28	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing zolpidem
US20060198790A1 (en) *	1997-10-01	2006-09-07	Dugger Harry A Iii	Buccal, polar and non-polar spray containing ondansetron
US20060210484A1 (en) *	1997-10-01	2006-09-21	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing testosterone
US20060216241A1 (en) *	1997-10-01	2006-09-28	Novadel Pharma Inc.	Buccal, polar and non-polar spray containing diazepam
US7087215B2 (en)	1998-12-21	2006-08-08	Generex Pharmaceuticals Incorporated	Methods of administering and enhancing absorption of pharmaceutical agents
US6849263B2 (en)	1998-12-21	2005-02-01	Generex Pharmaceutical Incorporated	Pharmaceutical compositions for buccal delivery of pain relief medications
US20030157029A1 (en) *	1998-12-21	2003-08-21	Pankaj Modi	Methods of administering and enhancing absorption of pharmaceutical agents
US20030035831A1 (en) *	1998-12-21	2003-02-20	Pankaj Modi	Pharmaceutical compositions for buccal delivery of pain relief medications
US6846495B2 (en)	1999-01-11	2005-01-25	The Procter & Gamble Company	Compositions having improved delivery of actives
US20060073174A1 (en) *	2001-08-16	2006-04-06	Access Pharmaceuticals, Inc.	Adherent and erodible film to treat a moist surface of a body tissue
US6585997B2 (en)	2001-08-16	2003-07-01	Access Pharmaceuticals, Inc.	Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds
US7138133B2 (en)	2001-10-10	2006-11-21	The Procter & Gamble Company	Orally administered liquid compositions
US20100063111A1 (en) *	2002-01-21	2010-03-11	Lindell Katarina E A	Formulation and use and manufacture thereof
US20030159702A1 (en) *	2002-01-21	2003-08-28	Lindell Katarina E.A.	Formulation and use manufacture thereof
US20070163610A1 (en) *	2002-01-21	2007-07-19	Pharmacia Ab	Formulation and Use and Manufacture Thereof
US9861586B2 (en)	2002-04-25	2018-01-09	Patheon Softgels, LLC	Chewable soft capsules
US8241665B2 (en)	2002-04-25	2012-08-14	Banner Pharmacaps, Inc.	Chewable soft capsule
US10342763B2 (en)	2002-04-25	2019-07-09	Patheon Softgels, Inc.	Chewable soft capsules
US8414916B2 (en)	2002-04-25	2013-04-09	Banner Pharma Caps, Inc.	Chewable soft capsule
US20050169983A1 (en) *	2002-04-25	2005-08-04	Hassan Emadeldin M.	Chewable soft capsule
US8765174B2 (en)	2002-04-25	2014-07-01	Banner Pharmacaps Inc.	Chewable soft capsule
US9072677B2 (en)	2002-04-25	2015-07-07	Banner Life Sciences Llc	Chewable soft capsules
US9668976B2 (en)	2002-04-25	2017-06-06	Banner Life Sciences, LLC	Chewable soft capsules
US8097279B2 (en)	2002-04-25	2012-01-17	Banner Pharmacaps Inc.	Chewable soft capsule
US20100256210A1 (en) *	2003-01-23	2010-10-07	Singh Nikhilesh N	Methods and compositions for delivering 5-ht3 antagonists across the oral mucosa
US20080213363A1 (en) *	2003-01-23	2008-09-04	Singh Nikhilesh N	Methods and compositions for delivering 5-HT3 antagonists across the oral mucosa
US20040198646A1 (en) *	2003-02-20	2004-10-07	Moshe Flashner-Barak	Menthol solutions of drugs
US20060062812A1 (en) *	2003-03-11	2006-03-23	Calvin Ross	Novel compositions
US20050136104A1 (en) *	2003-12-17	2005-06-23	Dennis Rowe	Chewable soft capsules containing ungelatinized starch
WO2005058242A2 (en)	2003-12-17	2005-06-30	R.P.Scherer Technologies, Inc.	Chewable soft capsules containing ungelatinized starch
US9241902B2 (en)	2003-12-17	2016-01-26	R.P. Scherer Technologies, Llc	Chewable soft capsules containing ungelatinized starch
US20100291004A1 (en) *	2004-02-17	2010-11-18	Singh Nikhilesh N	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20050226925A1 (en) *	2004-02-17	2005-10-13	Transoral Pharmaceuticals, Inc.	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7682628B2 (en)	2004-02-17	2010-03-23	Transcept Pharmaceuticals, Inc.	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7658945B2 (en)	2004-02-17	2010-02-09	Transcept Pharmaceuticals, Inc.	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US20080008753A1 (en) *	2004-02-17	2008-01-10	Singh Nikhilesh N	Compositions for delivering hypnotic agents across the oral mucosa and methods of use thereof
US7972621B2 (en)	2004-06-03	2011-07-05	R.P. Scherer Technologies, Llc	Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US20050271719A1 (en) *	2004-06-03	2005-12-08	Wong Desmond Y T	Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
WO2005120464A1 (en) *	2004-06-03	2005-12-22	R.P. Scherer Technologies, Inc.	Process for formulating fast dispersing dosage forms comprising at least one fish gelatin selected on the basis of molecular weight
US8940271B2 (en)	2005-02-17	2015-01-27	Abbott Laboratories	Transmucosal administration of drug compositions for treating and preventing disorders in animals
EP2767163A1 (de)	2005-02-17	2014-08-20	Abbott Laboratories	Transmukosale Verabreichung von Arzneimittelzusammensetzungen zur Behandlung und Vorbeugung von Erkrankungen bei Tieren
US8252809B2 (en)	2005-05-25	2012-08-28	Transcept Pharmaceuticals, Inc.	Compositions for treating insomnia
US20100249177A1 (en) *	2005-05-25	2010-09-30	Singh Nikhilesh N	Compositions and methods for treating middle-of-the-night insomnia
US20060276501A1 (en) *	2005-05-25	2006-12-07	Transoral Pharmaceuticals, Inc.	Solid compositions for treating middle-of-the-night insomnia
US20070066643A1 (en) *	2005-05-25	2007-03-22	Transoral Pharmaceuticals, Inc.	Methods of treating middle-of-the-night insomnia
US20070123562A1 (en) *	2005-05-25	2007-05-31	Transoral Pharmaceuticals, Inc.	Compositions and methods for treating middle-of-the-night insomnia
US20080057119A1 (en) *	2005-05-25	2008-03-06	Singh Nikhilesh N	Compositions and methods for treating middle-of-the night insomnia
US20110039881A1 (en) *	2005-05-25	2011-02-17	Singh Nikhilesh N	Compositions and methods for treating middle-of-the-night insomnia
US20070225322A1 (en) *	2005-05-25	2007-09-27	Transoral Pharmaceuticals, Inc.	Compositions and methods for treating middle-of-the night insomnia
US20070287740A1 (en) *	2005-05-25	2007-12-13	Transcept Pharmaceuticals, Inc.	Compositions and methods of treating middle-of-the night insomnia
US8242131B2 (en)	2005-05-25	2012-08-14	Transcept Pharmaceuticals, Inc.	Methods of treating middle-of-the-night insomnia
US20100249178A1 (en) *	2005-05-25	2010-09-30	Nikhilesh Singh	Compositions and methods for treating middle-of-the-night insomnia
US20070248548A1 (en) *	2006-04-19	2007-10-25	Blondino Frank E	Stable hydroalcoholic oral spray formulations and methods
WO2007146805A2 (en)	2006-06-08	2007-12-21	Warner Chilcott Company, Inc.	Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
US20100105641A1 (en) *	2006-12-12	2010-04-29	Kees Van Der Voort Maarschalk	Oral Contraceptive Spray
US20080171089A1 (en) *	2006-12-22	2008-07-17	Blondino Frank E	Stable anti-nausea oral spray formulations and methods
US9687495B2 (en)	2007-01-19	2017-06-27	Hananja Ehf	Methods and systems for the delivery of a therapeutic agent
US9289432B2 (en)	2007-01-19	2016-03-22	HANANJA EHF and UNIVERSITY OF ICELAND	Methods and compositions for the delivery of a therapeutic agent
US20090227568A1 (en) *	2007-01-19	2009-09-10	Sveinbjorn Gizurarson	Methods and compositions for the delivery of a therapeutic agent
US10052333B2 (en)	2007-01-19	2018-08-21	University Of Iceland	Methods and systems for the delivery of a therapeutic agent
US20080275030A1 (en) *	2007-01-19	2008-11-06	Sveinbjorn Gizurarson	Methods and Compositions for the Delivery of a Therapeutic Agent
US8217033B2 (en)	2007-01-19	2012-07-10	Hananja Ehf	Methods and compositions for the delivery of a therapeutic agent
US8809322B2 (en)	2007-01-19	2014-08-19	Hananja Ehf	Methods and compositions for the delivery of a therapeutic agent
WO2008091588A1 (en)	2007-01-22	2008-07-31	Targacept, Inc.	Intranasal, buccal, and sublingual administration of metanicotine analogs
US20080280947A1 (en) *	2007-05-10	2008-11-13	Blondino Frank E	Anti-insomnia compositions and methods
US20110040266A1 (en) *	2007-05-10	2011-02-17	Blondino Frank E	Anti-insomnia compositions and methods
WO2011064316A2 (en)	2009-11-25	2011-06-03	Paolo Botti	Mucosal delivery of peptides
WO2012022446A1 (en)	2010-08-16	2012-02-23	Innotesto Bvba	Testosterone solutions for the treatment of testosterone deficiency
US9402811B2 (en) *	2012-01-04	2016-08-02	Innotesto Bvba	Oromucosal liquid estradiol compositions
WO2013102665A1 (en)	2012-01-04	2013-07-11	Innotesto Bvba	Oromucosal liquid estradiol compositions
AU2013207215B2 (en) *	2012-01-04	2017-10-26	Innotesto Bvba	Oromucosal liquid estradiol compositions
US20140371191A1 (en) *	2012-01-04	2014-12-18	Innotesto Bvba	Oromucosal Liquid Estradiol Compositions
US20180177800A1 (en) *	2015-09-30	2018-06-28	Fujifilm Corporation	Composition for percutaneous absorption
WO2025090448A1 (en) *	2023-10-23	2025-05-01	R.P. Scherer Technologies, Llc	Capsules for oral and nasal delivery of pharmaceutical products

Also Published As

Publication number	Publication date
ES2234010T3 (es)	2005-06-16
AU2190697A (en)	1997-11-07
WO1997038662A2 (en)	1997-10-23
DE69732412T2 (de)	2006-01-05
DE69732412D1 (de)	2005-03-10
ATE288255T1 (de)	2005-02-15
WO1997038662A3 (en)	1998-02-12
PT910339E (pt)	2005-05-31
EP0910339B1 (de)	2005-02-02
EP0910339A2 (de)	1999-04-28

Legal Events

Date	Code	Title	Description
2000-05-08	AS	Assignment	Owner name: FLEMINGTON PHARMACEUTICALCORP., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DUGGER, HARRY A., III;REEL/FRAME:010794/0741 Effective date: 20000428
2000-08-10	STCF	Information on status: patent grant	Free format text: PATENTED CASE
2002-11-12	AS	Assignment	Owner name: NOVADEL PHARMA INC., NEW JERSEY Free format text: CHANGE OF NAME;ASSIGNOR:DUGGER, HARRY A., III;REEL/FRAME:013503/0407 Effective date: 20021001
2003-01-07	CC	Certificate of correction
2004-01-26	FPAY	Fee payment	Year of fee payment: 4
2008-01-29	FPAY	Fee payment	Year of fee payment: 8
2008-06-03	AS	Assignment	Owner name: PROQUEST INVESTMENTS III, L.P. AS COLLATERAL AGENT Free format text: SECURITY AGREEMENT;ASSIGNOR:NOVADEL PHARMA INC.;REEL/FRAME:021029/0574 Effective date: 20080506
2010-08-17	CC	Certificate of correction
2010-08-31	AS	Assignment	Owner name: NOVADEL PHARMA INC., NEW JERSEY Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:PROQUEST INVESTMENTS III, L.P. AS COLLATERAL AGENT;REEL/FRAME:024915/0277 Effective date: 20100830
2012-04-09	REMI	Maintenance fee reminder mailed
2012-04-30	FPAY	Fee payment	Year of fee payment: 12
2012-04-30	SULP	Surcharge for late payment	Year of fee payment: 11
2013-10-14	AS	Assignment	Owner name: SUDA LTD., AUSTRALIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:NOVADEL PHARMA INC.;REEL/FRAME:031401/0285 Effective date: 20130812

Publication	Publication Date	Title
US6110486A (en)	2000-08-29	Buccal polar spray or capsule
US5955098A (en)	1999-09-21	Buccal non polar spray or capsule
US6998110B2 (en)	2006-02-14	Buccal, polar and non-polar spray or capsule
JP2007507509A (ja)	2007-03-29	オンダンセトロン含有口腔内極性及び非極性スプレー
US7138135B2 (en)	2006-11-21	Bioadhesive, closed-cell foam film, sustained release, delivery devices and methods of making and using same
JP2006506342A (ja)	2006-02-23	消化管又は尿路の疾患を処置するための薬物を含有する、頬側の、極性及び非極性スプレイ又はカプセル
JP2006502149A (ja)	2006-01-19	アレルギー又は喘息治療用薬剤を含有する、口腔の、極性及び非極性スプレー又はカプセル
JP2006505611A (ja)	2006-02-16	疼痛治療用薬剤を含有する、口腔の、極性及び非極性スプレー又はカプセル
JP2006508052A (ja)	2006-03-09	筋肉及び骨障害治療用薬を含有する口腔内極性及び非極性噴霧剤又はカプセル剤
JPH05507085A (ja)	1993-10-14	ｎ―グリコフロール類及びｎ―エチレングリコール類を含有する医薬製剤
ES2611995T3 (es)	2017-05-11	Métodos y composiciones para el suministro de un agente terapéutico
CA2252038C (en)	2006-10-10	Buccal polar spray or capsule
US10172833B2 (en)	2019-01-08	Sublingual ondansetron spray
JP2009079060A (ja)	2009-04-16	極性または非極性の、バッカルスプレーまたはカプセル
CN112996488B (zh)	2025-03-14	唑吡坦或其药学上可接受的盐的口粘膜溶液
JP2009149675A (ja)	2009-07-09	極性または非極性の、バッカルスプレーまたはカプセル